Bioaffinity Technologies, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc. (BIAF) on August 12, 2025. The report details significant changes to the Company's Board of Directors and committee assignments effective as of the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Appointments: The Board appointed Roberto Rios, CPA, and John J. Oppenheimer, M.D., as new directors. Their initial terms expire at the 2026 annual meeting of stockholders.
- Board Resignation: Gary Rubin resigned from the Board and the Nominating and Corporate Governance Committee effective immediately. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Committee Reassignments:
- Roberto Rios was appointed Chair of the Audit Committee and a member of the Compensation Committee.
- John J. Oppenheimer was appointed to the Nominating and Corporate Governance Committee.
- Jamie Platt was appointed to the Audit Committee and as Chair of the Nominating and Corporate Governance Committee.
- Robert Anderson was appointed to the Compensation Committee.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on business operations. There are no related party transactions requiring disclosure for the new directors, and their annual compensation will be consistent with other non-employee directors. A press release regarding these appointments was issued on August 18, 2025.
Key Facts for Investor Verification
- Verify the professional backgrounds and potential conflicts of interest for new directors Roberto Rios and John J. Oppenheimer.
- Confirm the composition of the Audit, Compensation, and Nominating and Corporate Governance Committees following the reassignments.
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for these board changes.
- Note that the resignation of Gary Rubin was voluntary and unrelated to any disputes with the Company.